Taiho exercises option for Arcus Biosciences’ quemliclustat in Asia
2024-07-09
Preview
来源: Pharmaceutical Technology
The asset is currently being investigated as a potential treatment for metastatic pancreatic ductal adenocarcinoma. MattL_Images/Shutterstock.
Taiho Pharmaceutical has exercised an option for an exclusive licence to develop and commercialise Arcus Biosciences’ quemliclustat (AB680) in Japan and Asian territories, excluding mainland China.
This is the fourth time Taiho has opted into an Arcus programme under the ongoing collaboration between the two companies which began in 2017.
Taiho will make an option exercise payment.
Additional milestones payments are contingent on meeting clinical, regulatory and commercial goals.
Taiho will also pay royalties on net sales if the product is approved.
See Also:Hong Kong approves Leqembi for Alzheimer’s treatment
Preview
来源: Pharmaceutical Technology
Rgenta Therapeutics’ RGT-61159 gains IND approval to treat cancers
Preview
来源: Pharmaceutical Technology
An investigational small molecule CD73 inhibitorCD73 inhibitor, quemliclustat is being investigated as a potential treatment for metastatic pancreatic ductal adenocarcinoma (mPDAC).
Arcus plans to launch the global, registrational Phase III study PRISM-1 in 2024, which will assess quemliclustat plus chemotherapy against chemotherapy alone in previously untreated mPDAC patients.
The decision to progress to Phase III trials stems from promising overall survival results from the Phase Ib ARC-8 study.
With this licensing agreement, Taiho will support the development and potential commercialisation of quemliclustat and will also manage the operational aspects of the PRISM-1 study in Japan.
Taiho has already secured exclusive development and commercialisation rights for four Arcus programmes in Japan and Asian regions excluding mainland China.
These include the CD73 inhibitorCD73 inhibitor programme (quemliclustat), the dual A2a/b adenosine receptor antagonist programme (etrumadenant), the anti-PD-1 programme (zimberelimab), and the anti-TIGIT programme (domvanalimab and AB308).
Gilead Sciences holds the rights to commercialise quemliclustat in the US and co-promote with Arcus, as well as exclusive rights to develop and commercialise the product outside the US.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。